Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04062552
Other study ID # URCC18110CD
Secondary ID NCI-2019-02246UR
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date July 6, 2021
Est. completion date September 30, 2025

Study information

Verified date December 2023
Source University of Rochester
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial studies the delivery of the ENABLE palliative care program for patients with advanced cancer. The study compares two methods for delivering ENABLE: Virtual Learning Collaborative (VLC) and Technical Assistance (TA). The focus of the ENABLE palliative care program is on living well, managing stress, patient communication of their personal values and hopes for care, social support, and symptom management. This study may help practices to incorporate ENABLE palliative care services and improve overall mood and quality of life for patients with advanced cancer.


Description:

This cluster-randomized controlled study evaluates two strategies to implement the ENABLE (Educate, Nurture, Advise, Before Life Ends) early palliative care (EPC) program, while gathering additional information on the ENABLE clinical program and related outcomes. The primary aim is to gather preliminary data on the effectiveness of VLC or TA on ENABLE program uptake, defined as the proportion of patients that complete a Palliative Care Assessment and at least 4 ENABLE sessions. Secondary aims evaluate the preliminary effectiveness of VLC or TA on patient-level outcomes and the relationship between ENABLE program uptake and patient outcomes. Exploratory aims evaluate the preliminary effectiveness of VLC or TA on overall ENABLE program implementation, as measured by the General Organizational Index (GOI) and the relationship between overall ENABLE program implementation and patient outcomes. To achieve the study aims, at least 16 participating sites will be randomized to the Virtual Learning Collaborative study arm (VLC, n = 8 practices) or the Technical Assistance study arm (TA, n = 8 practices). Participating sites randomized to the VLC will have access to monthly group calls with an ENABLE expert and a quality improvement expert for up to 65 weeks. Participating sites randomized to TA will have access to monthly technical assistance support for their practice for up to 65 weeks. Each practice cluster will have a recruitment goal of 13 patients (target n=208 patients total; 104 patients per arm; allowable range per practice cluster 8-25). To account for practice clusters that may be unable to recruit at least 13 patients, we will include an option to recruit 4 additional practices per study arm. Patients who agree to participate in this study will consent to a clinician-led clinical Palliative Care Assessment and up to 6 semi-structured ENABLE telehealth 20-45 minute sessions, and up to 6 monthly follow-up calls over 26 weeks with an ENABLE Coach. Patients will complete assessments of mood and quality of life at baseline (within 14 days of study enrollment), 12 weeks (±2 weeks) and 24 weeks (±2 weeks).


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 208
Est. completion date September 30, 2025
Est. primary completion date September 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility PATIENTS Inclusion Criteria: - Age = 18 - English-speaking - Willing to complete palliative care assessment and ENABLE sessions. - Diagnosed within the last 90 days with an advanced cancer (defined as a newly diagnosed stage III/IV, recurrence, or progressive solid tumor cancer). * Patients can receive any cancer treatment for their advanced cancer while participating in this study. - Expected survival of at least 6 months - Have access to telephone that can receive incoming calls. - Able to provide informed consent. Exclusion Criteria: - Received previous palliative care services (Concurrent palliative care is allowed). PRACTICE SITES Inclusion Criteria: - All participating practice clusters will be asked to identify one (or more) ENABLE Coaches as part of study eligibility to deliver the ENABLE program. - Commitment of the ENABLE Coach(es) to be trained to conduct the palliative care assessment (and ENABLE sessions if the practice plans to implement them). - Desire to implement ENABLE, including presence of an investigator (e.g., Primary Affiliate PI, oncology physician, CCDR Lead) and/or program administrator/supervisor who are willing to be key contacts. - Demonstrated support/buy-in from oncology physicians who are willing to enroll patients. - Agreement of practice leadership and other individuals at the practice cluster to support/participate in the study activities - If necessary, willingness to participate in a phone interview to determine capacity to implement the ENABLE program. ONCOLOGY PHYSICIAN Inclusion Criteria: - Oncology Physician (i.e., medical oncologist or radiation oncologist including trainees) caring for oncology patients. - Oncology physicians must work at a participating practice cluster with no plans to leave that practice site or retire at the time of enrollment into the study. ENABLE COACH Inclusion Criteria: - A registered nurse or advanced practice provider (including a nurse practitioner or physician assistant), a physician (e.g., medical and radiation oncologists, including oncology trainees), or other professionals (e.g., social workers, chaplains) with appropriate credentials and experience to deliver ENABLE. - Individuals with an appropriate clinical license (i.e., a registered nurse, advanced practice provider, or physician, as defined above) may perform the Palliative Care Assessment and any ENABLE sessions and follow-up calls the practice chooses to deliver. - Other professionals (e.g., social workers, chaplains) may deliver ENABLE sessions and monthly follow-up calls for which their credentials and experience are appropriate. - ENABLE Coaches are required to complete appropriate study training for any content delivered.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Virtual Learning Collaborative
Patients undergo a palliative care assessment, participate in up to 6 ENABLE telehealth sessions with an ENABLE coach (20-45 minutes each), and complete up to 6 monthly follow-up calls over a 26-week period. The practice sites participate in a VLC consisting of group-based learning sessions, coaching, and applied quality improvement data collection, analysis and feedback opportunities monthly for up to 15 months.
Technical Assistance
Patients undergo a palliative care assessment, participate in up to 6 ENABLE telehealth sessions with an ENABLE coach (20-45 minutes each), and complete up to 6 monthly follow-up calls over a 26-week period. The practice sites undergo practice-based consultation calls with an ENABLE/TA expert monthly for up to 15 months.

Locations

Country Name City State
United States Michigan Cancer Research Consortium Ann Arbor Michigan
United States ThedaCare Appleton Wisconsin
United States Bon Secours Saint Francis Hospital Charleston South Carolina
United States Columbus NCORP Columbus Ohio
United States Geisinger Cancer Institute Danville Pennsylvania
United States Geisinger Medical Center Danville Pennsylvania
United States Iowa-Wide Oncology Research Coalition Des Moines Iowa
United States Aspirus Regional Cancer Center Green Bay Wisconsin
United States Prisma Health System Greenville South Carolina
United States Hawaii Minority Underserved NCORP Honolulu Hawaii
United States Hawaii MU NCORP Honolulu Hawaii
United States Northwell Health/Center for Advanced Medicine Lake Success New York
United States University of Rochester Rochester New York
United States Upstate Carolina NCORP Spartanburg South Carolina
United States Cancer Research for the Ozarks NCORP (CTEP ID: AR012) Springfield Missouri
United States Cancer Research for the Ozarks NCORP (CTEP ID: IL127) Springfield Missouri
United States Cancer Research for the Ozarks NCORP (CTEP ID: IL148) Springfield Missouri
United States Cancer Research for the Ozarks NCORP (CTEP ID: MO043) Springfield Missouri
United States Cancer Research for the Ozarks NCORP (CTEP ID: MO097) Springfield Missouri
United States Cancer Research for the Ozarks NCORP(CTEP ID: MO021) Springfield Missouri
United States MedStar Washington Hospital Center Washington District of Columbia
United States Roper Hospital Winston-Salem North Carolina
United States Southeast Clinical Oncology Research Consortium Winston-Salem North Carolina

Sponsors (3)

Lead Sponsor Collaborator
University of Rochester NCORP Research Base National Cancer Institute (NCI), University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary ENABLE Program Uptake ENABLE program uptake is defined as the proportion of enrolled patients at participating NCORP practices that complete a Palliative Care Assessment and at least 4 ENABLE sessions. To capture ENABLE program uptake, participating practices will use standardized logs to capture individuals offered the program, enrollment, and completion of the essential ENABLE elements (i.e., palliative care assessment, ENABLE telehealth sessions, follow-up calls). 65 weeks
Secondary Hospital Anxiety and Depression Scale (HADS) Survey to measure patient mood. Baseline, 12 weeks, 24 weeks
Secondary Functional Assessment of Chronic Illness-Palliative Care (FACIT-PAL) Survey to measure patient quality of life. Baseline, 12 weeks, 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05508100 - Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors Phase 1
Not yet recruiting NCT05515185 - B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors Early Phase 1
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT02836600 - A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04890613 - Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1/Phase 2
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06007482 - A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT04108676 - Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects Phase 1
Recruiting NCT05798611 - Study of ART0380 in Patients With Biologically Selected Solid Tumors Phase 2
Recruiting NCT05076396 - PM14 Administered Intravenously to Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06008366 - A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06054932 - Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors Phase 1
Recruiting NCT04825392 - A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06365918 - Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis Phase 1
Recruiting NCT05569057 - A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma Phase 1
Recruiting NCT05461287 - Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05443126 - A Study of EP0031 in Patients With Advanced RET-altered Malignancies Phase 1/Phase 2